Implementing Molecular Diagnostics in Clinical Oncology

With the advent of NGS technologies, targeted immunotherapies, and biomarker-based interventions, clinical oncology is one of the areas of medicine with the highest potential impact for precision medicine approaches. New therapies and diagnostics offer great opportunities, but also raise significant questions regarding which tests to offer, how to integrate these into existing organizations and regular clinical practice, and how to ensure access to cutting-edge therapies while maintaining diagnostic safety and quality measures.

 As part of the BigMed project we aimed to map out the organizational structures, processes, and systems that support molecular diagnostics for cancer at various institutions across the Nordics. By interviewing enough stakeholders from different institutions, we have described common trends and generalized learnings. Our hope is that this work can give visibility to the shared challenges and paths forward that allow more effective molecular diagnostics and ultimately better cancer care.   

Download the report here: Implementing NGS-based diagnostics in cancer care: Technical and organizational factors in the Nordics 


"Our goal is to (...) contribute to more effective molecular diagnostics, and ultimately better cancer care."

Information gathering

At each institution, had at a 1-2 day series of interviews where we discuss processes, systems, organizations, and the patient/sample pathway. Based on this, our notes sere sent out with a drafted process map and some follow-up questions to check for correctness. 

Goal

After gathering information from various stakeholders, key learnings were synthesized in a report - here.  

A project like this is only possible if a broad range of participants are willing to take time out of their already-full schedules to share their knowledge and opinions. Our goal is to make sure these viewpoints are faithfully represented, and hopefully give some visibility to the common challenges and solutions that can contribute to more effective molecular diagnostics, and ultimately better cancer care. 

Status:

Finished

Partners:

DNV, Karolinska Institutet, Oslo Universitetssykehus

Topics

Bioinformatics,

Genomics,

Infrastructure

Courtney Nadeau

DNV GL

+47 458 47 325

Send email

Vibeke Binz Vallevik

Prosjektleder BigMed / DNV GL

DNV GL Precision Medicine research / OUS Intervention Center

+47 930 36 931

Send email

Relevant Projects

Close up photo of test equipment in a lab

Benchmarking as a tool for quality in genetic testing

Ensuring accuracy in genomic medicineModern medical tests based on DNA and RNA sequencing are composed of a pipeline of numerous hardware systems, complex proprietary and open-source software, custom-built scripts, and manual,

Comprehensive clinical report from molecular diagnostics in cancer

Comprehensive clinical report from molecular diagnostics in cancer

Cancer is a genetic disease, as DNA is altered in each tumor. The changes differ greatly between different tumors and over time in a tumor. Many changes can occur in each tumor, and these changes may represent targets for therapy, or serve
Newborn baby holding parents hands

Variant eXchange - sharing of genomic variants classification between trusted partners

Improving genetic variant interpretation through data sharing with trusted partners of choice.